Skip to main content

Table 2 Clinical characteristics and outcome of patients with community-acquired pneumonia (CAP) and no-CAP controls

From: Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients

  CAP No CAP P
n = 271 n = 73
Demographics    
 Age, years, mean (SD) 59.7 (16.7) 58.8 (17.2) 0.70
 Gender, male, n (%) 155 (57.2) 40 (54.8) 0.79
 Race, white, n (%) 236 (87.1) 57 (78.1) 0.04
 Body mass index, kg/m2, mean (SD) 24.9 (6.0) 26.4 (9.4) 0.21
 Charlson score, median (IQR) 4 (2–6) 3 (2–5) 0.07
Severity of disease in first 24 hours    
 APACHE IV score, median (IQR) 79 (62–101) 68 (52–99) 0.07
 SOFA score, median (IQR)a 7 (4–9) 6 (3–7) 0.01
 Shock, n (%) 71 (26.2) 10 (13.7) 0.03
 Mechanical ventilation, n (%) 203 (74.9) 57 (78.1) 0.66
 Renal replacement therapy, n (%) 19 (7) 4 (5.5) 0.78
Outcome    
 ICU length of stay, days, median (IQR) 5 (2–11) 2 (1–4) <0.0001
 ICU mortality, n (%) 53 (19.6) 9 (12.3) 0.18
 30-day mortality, n (%) 73 (26.9) 16 (21.9) 0.37
 90-day mortality, n (%) 92 (33.9) 19 (26) 0.16
 1-year mortality, n (%) 121 (44.6) 30 (41.1) 0.50
  1. All patients were treated for suspected CAP upon ICU admission and classified in retrospect as having or not having CAP, as described in “Methods”. aCentral nervous system not included in score. APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment